You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial
|
|---|---|
| Published in |
Annals of Oncology, September 2015
|
| DOI | 10.1093/annonc/mdv373 |
| Pubmed ID | |
| Authors |
A. Davidson, A.-S. Veillard, A. Tognela, M.M.K. Chan, B.G.M. Hughes, M. Boyer, K. Briscoe, S. Begbie, E. Abdi, C. Crombie, J. Long, A. Boyce, C.R. Lewis, S. Varma, A. Broad, N. Muljadi, S. Chinchen, D. Espinoza, X. Coskinas, N. Pavlakis, M. Millward, M.R. Stockler, on behalf of the Australasian Lung cancer Trials Group, Brett Hughes, Michael Boyer, Karen Briscoe, Andrew Davidson, Stephen Begbie, Ehtesham Abdi, Catherine Crombie, Jeremy Long, Kevin Jasas, Craig Lewis, Adam Boyce, Suresh Vama, Adam Broad, Vy. Broaddge, David Gibbs, Robert Blum, Sue-Anne McLachlan, Andrew Haydon, Victoria Bray, Janette Vardy, Girish Mallesara, Ray Lowenthal, Ray Asghari, Susan Tiley, Theresa Hayes, Mohammed Islam, Steven Ackland, Jacqui Adams, Nick Pavlakis, Martin Stockler, Nick Muljadi, Xanthi Coskinas, Sarah Chinchen, Matthew Chan, Annette Tognela, Danielle Ferraro, Rasha Cosman |
| Abstract |
We sought to determine if the substantial benefits of topical nitroglycerin with first line, platinum-based, doublet chemotherapy in advanced non-small-cell lung cancer (NSCLC) seen in a phase 2 trial could be corroborated in a rigorous, multicenter, phase 3 trial. Patients starting one of five, pre-specified, platinum-based doublets as first line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression free survival (PFS) was the primary endpoint. Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS (median 5.0 v 4.8 months, HR=1.07, 95% CI 0.86 to 1.32, P=0.55), overall survival (median 11.0 v 10.3 months, HR=0.99, 95% CI 0.79 to 1.24, P=0.94), or objective tumor response (31% v 30%, relative risk=1.03, 95% CI 0.82 to 1.29, P=0.81). Headache, hypotension, syncope, diarrhea, dizziness and anorexia were more frequent in those allocated nitroglycerin. The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 45 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Student > Master | 5 | 11% |
| Other | 4 | 9% |
| Lecturer | 3 | 7% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 7 | 16% |
| Unknown | 17 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 20% |
| Nursing and Health Professions | 7 | 16% |
| Agricultural and Biological Sciences | 2 | 4% |
| Unspecified | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 6 | 13% |
| Unknown | 19 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2015.
All research outputs
#15,170,530
of 25,377,790 outputs
Outputs from Annals of Oncology
#5,719
of 7,854 outputs
Outputs of similar age
#136,115
of 279,004 outputs
Outputs of similar age from Annals of Oncology
#73
of 118 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,004 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.